Content area

|
|

Off-label-brug af psykofarmaka til børn og unge i Danmark

Forfatter(e)
Anne Katrine Pagsberg1, 2 & Per Hove Thomsen3, 4 1) Børne- og Ungdomspsykiatrisk Center, Forskningsenheden, Region Hovedstadens Psykiatri 2) Det Sundhedsvidenskabelige Fakultet, Københavns Universitet 3) Børne- og Ungdomspsykiatrisk Center, Aarhus Universitetshospital 4) Institut for Klinisk Medicin, Aarhus Universitet Ugeskr Læger 2017;179:V05170355
Reference: 
Ugeskr Læger 2017;179:V05170355
Blad nummer: 
Sidetal: 
2-6
Off-label prescription of psychopharmacological drugs for children and adolescents
Despite regulatory initiatives, psychopharmacological treatment of adolescents is challenged by missing trial data on efficacy and safety. An estimated mean off-label prescription rate of 30-40% in Danish clinical child- and adolescent mental health services (MHS) has been found. Lowest rates were found for ADHD drugs (2-3%) and highest for antipsychotics (96%) and melatonin (100%). The use of melatonin is growing, while the use of other psycho­pharmacological drugs seems stabilizing or decreasing in spite of more adolescents treated in Danish MHS.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Camilla Bang | 21/10
3 kommentarer
af Anne Gersdorff Korsgaard | 20/10
1 Kommentar
af Karen Brink Linnet | 19/10
1 Kommentar
af Thor Andersen Knudsen | 19/10
2 kommentarer
af Ole Lindgård Dollerup | 18/10
1 Kommentar
af Kristine Rasmussen | 18/10
1 Kommentar
af Camilla Bang | 16/10
1 Kommentar
af Tobias Ramm Eberlein | 15/10
6 kommentarer